Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyThu, 09 May 2024 06:44:11 +0200Fri, 05 Apr 2024 17:31:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip01-09-m14Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip01-09-m14Fri, 05 Apr 2024 17:31:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 29, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/xeljanzHuman medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 29, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/xeljanzThu, 07 Dec 2023 15:05:00 +0100Human medicineXeljanz-H-C-4214-X-0005 : EPAR - Assessment Report - Variationhttps://www.ema.europa.eu/system/files/documents/variation-report/wc500254119_en.pdfXeljanz-H-C-4214-X-0005 : EPAR - Assessment Report - Variationhttps://www.ema.europa.eu/system/files/documents/variation-report/wc500254119_en.pdfMon, 20 Aug 2018 13:16:00 +0200Human medicine